Abstract
Highlights
What are the main findings?
Peroxisomal functions decline with age, impairing protein import, lipid metabolism, redox balance, and organelle quality control.
Peroxisomes act as central signaling hubs, and their dysfunction propagates stress to mitochondria, the endoplasmic reticulum, and lysosomes.
What are the implications of the main findings?
Peroxisomal homeostasis supports healthy aging by contributing to cellular resilience and metabolic stability.
Peroxisomal pathways are emerging as therapeutic targets for age-related diseases and functional decline.
Abstract
Peroxisomes are multifunctional organelles that play essential roles in lipid metabolism, redox regulation, and cellular signaling. An expanding body of evidence implicates peroxisomal dysfunction as a key contributor to aging and age-related diseases. Aging is accompanied by progressive declines in key peroxisomal functions, including catalase activity, fatty acid β-oxidation, plasmalogen biosynthesis, and the metabolism of bile acids and docosahexaenoic acid, resulting in increased oxidative stress, lipid dysregulation, and alterations in membrane composition. Impaired pexophagy further exacerbates these defects by allowing the accumulation of damaged peroxisomes and compromising cellular homeostasis. Through extensive metabolic and signaling crosstalk with mitochondria, the endoplasmic reticulum, and lysosomes, peroxisomal dysfunction can propagate oxidative and metabolic disturbances throughout the cell. In addition, peroxisome-derived signaling molecules, such as hydrogen peroxide and bioactive lipids, link peroxisomal activity to cellular stress responses and organismal metabolic homeostasis. We propose that aging-associated impairments in peroxisomal protein import, redox regulation, and selective turnover progressively shift peroxisomes from adaptive metabolic signaling hubs toward sources of chronic oxidative and lipid stress. In this context, current studies highlight peroxisomal homeostasis as a potential determinant of healthy aging and point to peroxisomal pathways as emerging targets for intervention in age-related disease.
Keywords: aging, catalase, interorganelle crosstalk, lipid metabolism, metabolic disorders, neurodegeneration, peroxisomes, pexophagy, reactive oxygen species, therapeutic interventions
1. Introduction
Aging is a natural process that progressively compromises human health by affecting multiple biological and physiological systems, including metabolism, organ function, cognition, and immune competence, ultimately reducing mobility, independence, and quality of life [1,2,3,4]. Although these changes increase vulnerability to chronic and neurodegenerative diseases, lifestyle factors such as regular physical activity, balanced nutrition, intermittent fasting, cognitive stimulation, and social engagement can delay or attenuate many age-related declines, highlighting the potential for interventions that promote healthy aging [5,6]. At the cellular level, aging reflects the cumulative impact of intrinsic processes—including genomic instability, telomere shortening, organelle dysfunction, oxidative stress, and cellular senescence—that disrupt tissue homeostasis and drive disease susceptibility [7]. Understanding how these mechanisms intersect is essential for elucidating the biological basis of aging. In this review, we synthesize emerging evidence that implicates age-associated deterioration of peroxisomal homeostasis—characterized by impaired protein import, redox imbalance, and defective turnover—as a contributor to metabolic dysfunction and age-related disease, and we discuss how maintaining peroxisomal integrity may support cellular resilience during aging.
2. Peroxisomal Functions and Their Role in Aging
Peroxisomes are single-membrane organelles found in nearly all mammalian cells [8], with the exception of mature erythrocytes [9], spermatozoa [10], and lens fibers [11]. They are essential for lipid metabolism, redox balance, and cellular signaling [12,13]. Peroxisomes perform key metabolic processes, including the α- and β-oxidation of various lipophilic carboxylic acids [14], the biosynthesis of plasmalogens [15] and docosahexaenoic acid (DHA) [16], the production and detoxification of hydrogen peroxide (H2O2) via flavin-containing oxidases and catalase, respectively [17], and the breakdown of xenobiotic acyl compounds [18]. Age-related declines in peroxisomal function result in the accumulation of very-long-chain and branched-chain fatty acids, a reduction in plasmalogens, and increased oxidative stress, contributing to metabolic dysfunction and redox imbalance, as observed in Alzheimer’s disease patients [19] and a corresponding mouse model [20]. Because many of these metabolic and redox processes are closely shared with other organelles, including mitochondria [21], peroxisomal decline is expected to have broader consequences for cellular homeostasis.
Mitochondrial function is essential for maintaining health, and its progressive decline is a hallmark of aging [7]. Many cellular processes that preserve mitochondrial integrity—such as lipid metabolism and reactive oxygen species (ROS) homeostasis—rely on close cooperation with peroxisomes [22,23]. Despite this critical interplay, peroxisomes are often overlooked in mitochondria-centered theories of aging. They support mitochondrial performance by regulating lipid metabolism and controlling the levels of signaling molecules, including H2O2 and bioactive lipids such as DHA-derived mediators and neuroprotective lipids [16,17,24,25], which feed into cellular signaling networks to modulate stress responses and enhance resilience. Through dynamic interactions with mitochondria and other organelles—including the endoplasmic reticulum (ER), lysosomes, and lipid droplets [22,26]—peroxisomes coordinate metabolic and signaling processes that sustain organismal health. Both inherited defects and age-related functional decline can disrupt these interorganellar networks, underscoring peroxisomes as crucial, yet often underappreciated, regulators of aging and age-related diseases [27,28,29,30].
3. Aging-Associated Peroxisomal Dysfunction
Aging has a pronounced impact on peroxisomes, influencing their abundance, enzymatic composition, and overall functional capacity in a cell- and tissue-specific manner [31,32,33,34]. These age-related changes result from multiple factors, including reduced peroxisome biogenesis, altered peroxisomal protein expression, impaired protein import, and modified peroxisome turnover. Collectively, these changes drive the progressive decline of peroxisomal function with age, which is examined in detail in the following sections focusing on biogenesis, protein import, quality control, H2O2 handling, and lipid metabolism (Figure 1).
Figure 1.
Age-associated decline in peroxisome homeostasis and function. Aging induces multifactorial alterations in peroxisome (PO) biology, including reduced peroxisome biogenesis and protein import, dysregulated organelle turnover via pexophagy, increased oxidative stress, and impaired lipid metabolic functions (depicted as β-ox), such as fatty acid β-oxidation, plasmalogen biosynthesis, bile acid metabolism, and docosahexaenoic synthesis. Collectively, these changes lead to age-related alterations in peroxisome number and composition, thereby promoting oxidative stress, lipid imbalance, and disrupted interorganelle communication. The PEX5 (5) docking/translocation machinery is shown in yellow, and the autophagic machinery involved in pexophagy is depicted in blue. ↑ indicates an increase; ↓ indicates a decrease; thicker arrows represent stronger effects; and the red circular regulatory symbol indicates reduced pexophagy. CAT, catalase; ER, endoplasmic reticulum; MT, mitochondria.
3.1. Peroxisome Biogenesis and Protein Import
New peroxisomes are generated either de novo from pre-peroxisomal vesicles originating from the ER or mitochondria; or through the growth and division of existing organelles [35,36,37]. Their assembly and maturation are orchestrated by peroxins (PEX), which coordinate vesicle formation as well as the import of membrane and matrix proteins [38]. PEX16, a peroxisomal membrane protein (PMP), is required for ER-derived vesicle formation [35], whereas mitochondria-derived vesicles involve PEX3 and PEX14 [39,40]. PEX19 functions as a cytosolic chaperone and import factor for PMPs [41], whereas PEX5 and PEX7 act as cycling receptors for matrix proteins containing C-terminal (PTS1) or N-terminal (PTS2) peroxisomal targeting signals, respectively [42]. PEX5-cargo complexes dock at PEX13 and PEX14, allowing cargo translocation followed by PEX5 recycling [42]. Recycling occurs in two steps: first, PEX5 is monoubiquitinated on a conserved and redox-sensitive cysteine (Cys11 in humans) and retrotranslocated via the PEX2-PEX10-PEX12 ubiquitin ligase complex, which facilitates PEX5 unfolding and cargo release [43,44]; second, the PEX1-PEX6 ATPase, anchored to the membrane by PEX26, extracts PEX5 from the membrane in a process analogous to ER-associated degradation [45]. Mature peroxisomes proliferate through elongation, constriction, and fission, a process regulated by proteins such as PEX11α/β, fission protein 1, and dynamin-like protein 1 [46].
It is well established that cellular aging, a process associated with increased oxidative stress, affects PEX5 functionality [32,34,47,48,49]. Aging and oxidative stress impair PEX5 recycling, leading to its accumulation on the peroxisomal membrane and reducing the import of matrix proteins, particularly those with weak PTS1 signals [50]. A prominent example is catalase, which is retained in the cytosol under oxidative stress; together with the redox-regulated activity of PEX5, this serves as a cellular defense mechanism against oxidative insults originating outside the peroxisome [50] (Figure 1). Furthermore, both cellular and organismal aging have been shown to downregulate numerous peroxisomal proteins, including key factors required for peroxisome biogenesis. This includes PEX3 and PEX5 in Caenorhabditis elegans [48]; PEX5 in aged Drosophila oenocytes and intestinal stem cells, as well as in aged mouse intestinal stem cells [49,51]; and PEX2, PEX5, PEX10, PEX12, and PEX19 in humans [52]. As a result, both peroxisome biogenesis and enzymatic composition are altered with age, a pattern confirmed in human B-cells [34] and in subproteomic analyses of aged mouse liver and kidney peroxisomes [33]. Collectively, these findings demonstrate that peroxisome homeostasis—encompassing both quantity and functionality—is compromised during aging.
3.2. Peroxisomal Quality Control
Peroxisome homeostasis is maintained by a dynamic balance between organelle biogenesis and selective degradation through pexophagy, a specialized form of autophagy. Like other selective autophagy pathways, such as mitophagy, pexophagy can proceed via ubiquitin-dependent or ubiquitin-independent mechanisms to eliminate damaged or excess peroxisomes, thereby supporting metabolic flexibility. The molecular machinery underlying pexophagy has been reviewed in detail elsewhere [53,54,55].
Aging profoundly impairs autophagy [56], characterized by chronic mTOR activation [57], reduced AMPK and SIRT1-signaling [58,59], decreased expression and activity of core autophagy-related proteins [60], and increased oxidative stress impairing genomic instability [61], which together compromise autophagic flux and lysosomal function. Although direct longitudinal studies of pexophagy during organismal aging are limited [62,63,64], evidence from autophagy-deficient models [65] and senescent cells [66] suggests that pexophagy is similarly disrupted, leading to the accumulation of dysfunctional peroxisomes and heightened cellular stress (Figure 1).
3.3. Peroxisomal H2O2 Metabolism
Peroxisomes generate considerable amounts of H2O2 through the activity of flavin-containing oxidases, which participate in the β-oxidation of very-long-chain fatty acids (VLCFAs), pristanic acid, poly-unsaturated fatty acids (PUFAs), and bile acid intermediates, as well as the metabolism of D-amino acids (e.g., D-serine and D-aspartate), L-hydroxy acids (e.g., glycolate), polyamines (e.g., N1-acetylspermine), and L-pipecolic acid [67]. Catalase serves as the primary H2O2-scavenging enzyme. Aging is associated with reduced catalase activity and mislocalization to the cytosol, compromising peroxisomal capacity to neutralize H2O2 and maintain redox balance [68]. Concurrent age-related impairments in pexophagy may lead to the accumulation of redox-compromised peroxisomes, further exacerbating functional decline. Because H2O2 can permeate across the peroxisomal membrane [69], excess H2O2 may spill into the cytosol, modulating H2O2-responsive signaling pathways at low concentrations or promoting oxidative stress at higher levels (Figure 1) [70]. Chronic pharmacological inhibition of catalase has been shown to induce cellular senescence, consistent with aging-associated phenotypes [32]. Despite these insights, many mechanistic details of how peroxisomal redox imbalance affects H2O2-mediated signaling and oxidative stress pathways remain to be elucidated.
3.4. Peroxisomal Lipid Metabolism
Peroxisomes are essential for the β-oxidation of specific fatty acids—including VLCFAs, pristanic acid, PUFAs, and bile acid intermediates—as well as for the biosynthesis of DHA and plasmalogens [13,14]. Many peroxisomal functions decline with age, including β-oxidation [71], plasmalogen biosynthesis [72], bile acid metabolism [52,73], and DHA synthesis [74] (Figure 1). Because these lipids and lipid intermediates play key roles in cellular signaling, membrane composition, and overall homeostasis, their dysregulation may contribute to age-associated cellular dysfunction [75]. Indeed, alterations in membrane phospholipids, PUFAs, plasmalogens, and DHA-containing or DHA-derived lipid mediators are correlated with age-related functional declines, including cognitive impairment, metabolic disturbances, and reduced lifespan [76]. Nevertheless, while these correlations are suggestive, direct causal links between peroxisomal lipid metabolism and lifespan in long-lived mammals and humans remain to be firmly established.
4. Peroxisomal Decline and Its Contribution to Age-Associated Pathologies
Peroxisomal metabolism, particularly fatty acid β-oxidation and H2O2 metabolism, may be modulated by lifestyle factors such as high-fat diets, smoking, alcohol consumption, and physical activity. Consistent with this possibility, several studies have reported associations between these exposures and changes in peroxisomal gene expression or catalase activity [77,78]; however, most available evidence is indirect or derived from animal models [14,79,80,81,82,83], and causal effects in humans remain uncertain. Nevertheless, it is well established that a decline in peroxisomal function can lead to lipid accumulation, alterations in membrane composition, impaired antioxidant defenses, metabolic dysfunction, and disrupted cellular signaling, all of which contribute to cellular aging and age-related pathologies (Figure 2) [76]. Decreased plasmalogen levels can compromise antioxidant protection and membrane stabilization, while DHA supports neuronal health by maintaining membrane fluidity, promoting synaptic function, and serving as a precursor for neuroprotectin D1, a mediator with anti-inflammatory and neuroprotective effects. Deficits in these pathways have been associated with cognitive decline. This section reviews current insights into the role of peroxisomes in various age-related diseases.
Figure 2.
Peroxisomal dysfunction contributes to hallmarks of cellular aging and is associated with age-related diseases. Some elements were adapted from BioRender (https://www.biorender.com; accessed on 22 December 2025) templates. The magnifying glass highlights an individual peroxisome. ↑ indicates an increase; ↓ indicates a decrease; For details, see the main text.
4.1. Neurodegenerative Disorders
Age-related neurodegenerative disorders, including Alzheimer’s disease (AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS), are characterized by chronic oxidative stress, neuroinflammation, and progressive disturbances in peroxisomal metabolism [84,85,86,87]. Plasmalogens, ether phospholipids whose biosynthesis is initiated in peroxisomes and completed in the endoplasmic reticulum, are highly enriched in neuronal membranes, where they contribute to membrane organization and dynamics, exert endogenous antioxidant activity, and support processes essential for synaptic integrity and neuronal function [88,89]. Consistent with these roles, plasmalogen deficiency is increasingly recognized as a common feature of neurodegenerative disorders and is thought to contribute to disease pathogenesis [90,91].
In AD, postmortem analyses have revealed accumulation of VLCFAs, reduced plasmalogen levels, increased oxidative stress, and region-specific, disease stage-dependent alterations in peroxisome density. Notably, peroxisomes are selectively lost from neurites of neurons containing abnormally phosphorylated tau, whereas neuronal somata in advanced stages of AD exhibit increased peroxisome volume density compared with less affected individuals [19,92]. Lipidomic studies have demonstrated marked reductions in plasmalogen that correlate with synaptic dysfunction, cognitive decline, and neuropathological staging in AD, supporting a contributory—and potentially causative—role in disease progression [19,88,93].
In PD, lipid composition analyses of frontal cortical lipid rafts reveal marked reductions in DHA compared with control brains [94]. PD is also associated with impaired peroxisomal β-oxidation and reduced plasmalogen levels, and experimental studies indicate that pharmacological stimulation of peroxisome proliferation can mitigate α-synuclein-associated toxicity [95]. Although direct causal evidence linking plasmalogen depletion to α-synuclein aggregation remains limited, restoration of plasmalogen levels using plasmalogen precursors protects dopaminergic neurons from toxin-induced degeneration in PD models [96], consistent with plasmalogen deficiency contributing to increased dopaminergic vulnerability. In addition, supplementation with plasmalogens or derivatives may improve cognitive functions in patients with mild AD and enhance spatial memory while reducing neuroinflammation in mice [97,98]. More broadly, alterations in neuronal lipid composition, including specific phospholipid classes, are known to modulate α-synuclein aggregation dynamics and pathogenicity [99]. Furthermore, DHA has demonstrated neuroprotective effects in multiple PD models [100,101,102].
In ALS, decreased levels of DHA-related β-oxidation enzymes have been reported [103], along with reduced expression of alkylglycerone-phosphate synthase, a key peroxisomal enzyme required for plasmalogen biosynthesis, in motor neuron disease models [104]. Mutations in the peroxisomal enzyme D-amino acid oxidase have also been linked to ALS, contributing to peroxisomal dysfunction and oxidative damage [105].
Collectively, these observations support the emerging concept that age-associated peroxisomal dysfunction disrupts peroxisomal lipid metabolism, including plasmalogens, representing a central metabolic alteration that contributes to neuronal vulnerability and disease progression across multiple neurodegenerative disorders.
4.2. Metabolic Disorders
Peroxisomes are central regulators of cellular lipid metabolism, oxidizing very-long-chain and complex fatty acids, generating signaling metabolites such as acetyl-CoA and H2O2, and synthesizing ether lipids [106,107]. Through these activities, they contribute to whole-body energy homeostasis, brown adipose tissue thermogenesis, lipolysis, lipid droplet turnover, and metabolic signaling [108,109]. Peroxisomes also engage in dynamic interactions with mitochondria, the ER, lipid droplets, and lysosomes, enabling coordinated lipid metabolism and interorganelle metabolite exchange [22].
The essential role of peroxisomes in human physiology is underscored by genetic disorders caused by defects in peroxisome biogenesis or enzyme function. These inborn errors of metabolism are characterized by severe multi-organ pathology, neurological impairment, and early mortality. Examples include Zellweger spectrum disorders, X-linked adrenoleukodystrophy, Refsum disease, and acyl-CoA oxidase deficiency [28,110]. Beyond these rare conditions, human and animal studies demonstrate that peroxisomes are critical regulators of obesity, dyslipidemia, and systemic glucose homeostasis [109,111,112].
In metabolic disease, peroxisomal dysfunction contributes directly to tissue-specific pathology. In nonalcoholic fatty liver disease (NAFLD), impaired peroxisomal metabolism promotes hepatic lipid accumulation and oxidative stress [79]. In obesity and hyperlipidemia, enhanced peroxisomal β-oxidation increases H2O2 production, contributing to pancreatic β-cell lipotoxicity and impaired insulin secretion, while reduced plasmalogen levels and altered ether lipid composition exacerbate diabetic neuropathy and other metabolic complications [108,113,114]. Accordingly, intact peroxisomal function is essential for β-cell integrity and insulin secretion [115]. Diabetes is further associated with impaired peroxisome biogenesis, resulting in increased ROS levels, blunted insulin secretion, and aggravated lipotoxicity [116]. Consistently, catalase deficiency accelerates diabetic renal injury by compromising peroxisomal redox homeostasis [117]. In white adipose tissue, obesity is linked to reduced expression of peroxisomal genes and diminished peroxisomal fitness, fostering oxidative stress and inflammation [112]. In line with these findings, lower circulating plasmalogen levels correlate with higher body mass index and increased metabolic risk [118,119].
Age-related disruption of peroxisomal function and interorganelle communication further exacerbates metabolic stress by impairing lipid mobilization, fatty acid metabolism, contact site-mediated metabolite transfer, and ER stress responses [29,120,121]. These alterations reduce metabolic flexibility, limiting the ability to switch energy substrates during fasting or dietary interventions [122]. With advancing age, changes in peroxisome biogenesis, enzyme activity, and signaling drive a progressive loss of metabolic flexibility—a hallmark of aging and a shared feature of metabolic syndrome and type 2 diabetes [123,124]—thereby increasing susceptibility to insulin resistance and hepatic steatosis [109,122]. Consequently, peroxisomal dysfunction is increasingly recognized as a central contributor to age-related metabolic diseases, including type 2 diabetes and its complications, NAFLD, metabolic syndrome, dyslipidemia, and obesity [29]. Beyond metabolic tissues, peroxisomal impairment in the nervous system is also increasingly implicated in neurodegeneration, where disrupted lipid homeostasis, defective myelin maintenance, and elevated oxidative stress comprise neuronal integrity [125].
4.3. Cancer
Peroxisomes exhibit a context-dependent, Janus-faced role in cancer, functioning either as tumor suppressors or as metabolic enablers depending on cellular state and disease stage [126]. Under homeostatic conditions, peroxisomes maintain redox and lipid balance through catalase-mediated detoxification and fatty acid metabolism, thereby preventing oxidative stress, genomic instability, and lipotoxicity. During aging, peroxisomal dysfunction can contribute to cellular senescence and the formation of a pro-tumorigenic microenvironment. In senescent cells, reduced peroxisomal catalase increases ROS levels, and altered lipid metabolism impairs membrane properties, both of which affect intracellular signaling [29,32,127,128,129]. Concurrently, impaired pexophagy leads to the accumulation of dysfunctional peroxisomes [66], further reducing metabolic flexibility, elevating oxidative stress, and causing the buildup of VLCFAs, collectively promoting chronic low-grade inflammation and facilitating cancer initiation [129,130,131,132]. Supporting this, reduced catalase expression correlates with poor prognosis in several cancers, partly due to enhanced ROS-driven oncogenic signaling [133,134].
Conversely, once tumors are established, peroxisomes are frequently co-opted to support cancer progression [135,136,137]. Peroxisomal β-oxidation supplies acetyl-CoA for lipid biosynthesis, H2O2 functions as a pro-tumorigenic signaling molecule, and plasmalogens enhance membrane dynamics, cell survival, and metastatic potential. Thus, while age-associated peroxisomal dysfunction initially promotes cellular senescence, selective reactivation and metabolic rewiring of peroxisomes during tumor initiation and progression support metabolic plasticity and contribute to malignant progression.
4.4. Inflammatory-Related Disorders
Peroxisomes play a critical role in modulating inflammation through lipid metabolism, redox homeostasis, and signaling pathways [130]. They degrade pro-inflammatory eicosanoids, including prostaglandins, thromboxanes, leukotrienes, and prostacyclins [138], while also contributing to the synthesis of PUFAs such as DHA, which are precursors of anti-inflammatory mediators including resolvins, maresins, and protectins [139,140]. Oxidative stress and inflammation mutually reinforce one another [131], modulating key inflammatory pathways such as NF-κB and MAPK [130].
Peroxisomal dysfunction disrupts lipid metabolism and redox homeostasis, leading to oxidative stress and dysregulated inflammatory responses [131]. For example, reduced peroxisomal β-oxidation causes accumulation of VLCFAs, which can promote the production of inflammatory mediators [14,132]. VLCFA buildup can further impair peroxisomal function, creating a self-amplifying cycle of inflammation [27,141].
An example of an age-related inflammatory pathology is multiple sclerosis (MS), a chronic autoimmune disease of the central nervous system characterized by neuroinflammation, demyelination, and axonal loss [142]. Although the mechanisms underlying MS are not fully understood, peroxisomes have been implicated in its pathogenesis [143]. In animal models, peroxisome deficiency in neural cells induces rapid neuroinflammation [144]. Experimental MS models exhibit reduced catalase activity, decreased plasmalogen levels, and VLCFA accumulation, which may increase tumor necrosis factor-alpha production and drive demyelination [145]. Consistently, tissues from MS patients show reduced neuronal peroxisome abundance alongside elevated VLCFA levels [146,147].
4.5. Premature Aging Syndromes
Progeroid syndromes exhibit features resembling normal aging, but these manifest earlier in life and progress rapidly. As such, they provide an accelerated model for studying aging mechanisms [148]. These syndromes can be broadly classified into two groups: (i) laminopathies, arising from defects in the nuclear lamina, and (ii) syndromes caused by defects in DNA repair or the DNA damage response [149,150].
Hutchinson-Gilford progeria syndrome (HGPS) is a laminopathy caused by mutations in the LMNA gene, leading to accumulation of progerin, a truncated form of the Lamin A protein. HGPS patients display accelerated aging phenotypes, including growth retardation, fat loss, hair thinning, bone erosion, and skin tightening, often resulting in early death due to cardiovascular complications [151]. Similarly to normal aging, HGPS is characterized by elevated ROS, stemming from mitochondrial dysfunction [152]. While peroxisome density remains unchanged in HGPS cells, antioxidant defenses are affected: catalase activity is significantly reduced [152], whereas glutathione peroxidase shows variable effects—decreasing in some studies [153] but unaffected in others [152]. HGPS cells also exhibit impaired protein import and reduced PEX5 expression, likely exacerbating oxidative stress and promoting cellular senescence [152].
Ataxia-telangiectasia (A-T), a representative example of the second group of progeroid syndromes, is caused by mutations in the ATM gene, which impair DNA break repair and result in genomic instability, cerebellar degeneration, immune deficiencies, increased cancer risk, and radiation hypersensitivity [150,154]. Under oxidative stress, ATM phosphorylates PEX5, promoting its ubiquitylation at the peroxisomal membrane and recognition by autophagy receptor p62, while simultaneously inhibiting mTORC1 to stimulate pexophagy [155]. In A-T patients, loss of functional ATM prevents proper mTORC1 repression [156], which may impair pexophagy and thereby contribute to elevated oxidative stress and cellular senescence.
4.6. Age-Associated Sarcopenia
Age-related sarcopenia is a progressive muscle disease that develops with aging and is characterized by the loss of muscle mass, strength, and function [157]. This condition increases the risk of falls, fractures, disability, and reduces quality of life [158].
A recent study reported that peroxisomes are essential for efficient lipid metabolism in muscle cells, and that peroxisomal dysfunction impairs muscle energy production and redox balance [25]. Muscle-specific deletion of PEX5 in mice caused early disruption in lipid and amino acid metabolism, resulting in reduced muscle force, poor exercise performance, and progressive mitochondrial degeneration. These alterations were accompanied by sarcomere and neuromuscular junction deterioration, protein aggregate accumulation, and muscle atrophy, leading to premature muscle aging. The study also demonstrated that peroxisomal content in muscle declines progressively with age, emphasizing the importance of maintaining peroxisomal function and its influence on mitochondrial fitness to preserve muscle health during aging [25].
5. Targeting Peroxisomes to Promote Healthy Aging
5.1. Peroxisomes as Active Regulators of Cellular Aging
Peroxisomes are increasingly recognized as active regulators of cellular aging rather than passive metabolic components [26]. Age-associated declines in peroxisome abundance and function contribute to lipid dysregulation and elevated oxidative stress—hallmarks strongly associated with functional decline and age-related disease [159]. Beyond their intrinsic metabolic roles, peroxisomes engage in extensive crosstalk with other aging-relevant organelles, particularly mitochondria, through shared lipid metabolic pathways and redox signaling [21]. Peroxisomal dysfunction can therefore compromise mitochondrial integrity and bioenergetic capacity, amplifying cellular stress and accelerating aging phenotypes [160,161,162]. Through these interactions, peroxisomes influence broader metabolic and stress-response pathways that are central to longevity regulation.
Genetic and metabolic studies have further demonstrated that peroxisomal homeostasis directly influences aging and lifespan. In C. elegans, lifespan extension from dietary restriction and AMPK signaling depends on mitochondrial network remodeling and communication with peroxisomes, highlighting peroxisomal involvement as a downstream mechanism of these interventions [163]. Similarly, in Drosophila, age-dependent impairment of peroxisomal protein import in oenocytes activates c-Jun N-terminal kinase (JNK) signaling and increases the pro-inflammatory cytokine unpaired 3 (Upd3) [49]. Upd3 acts as a circulating factor that non-autonomously drives cardiac aging, linking peroxisomal decline to systemic aging processes [49].
Additional studies in C. elegans support a pro-longevity role for peroxisomes through their regulation of lipid metabolism and redox balance. Dietary mono-unsaturated fatty acids (MUFAs) increase both lipid droplet and peroxisome abundance in fat storage tissues, and this coordinated upregulation is required for MUFA-induced lifespan extension [164]. Similarly, dietary supplementation with α-ketobutyrate extends lifespan by elevating NAD+ levels via lactate dehydrogenase 1 [165]. Increased NAD+ activates SIR-2.1, the worm homolog of SIRT1, which promotes peroxisome biogenesis and fatty acid β-oxidation. This metabolic shift enhances H2O2 production, activating the SKN-1/Nrf2 stress response pathway and thereby stimulating antioxidant defenses, autophagy, and mitochondrial function to promote longevity [165]. Moreover, peroxisomal ether lipid biosynthesis is required for lifespan extension across multiple pro-longevity paradigms, including treatment with the biguanide drug phenformin, a metformin analog [166]. Consistently, peroxisomal protein import, fatty acid elongases, and desaturases are essential for the longevity-promoting effects of biguanides, underscoring the critical role of peroxisomal lipid metabolism in aging regulation [166].
Collectively, these findings position peroxisomes as central regulators of aging, whose metabolic and signaling functions integrate with those of other organelles to influence organismal longevity.
5.2. Crosstalk Between Peroxisomes and Longevity-Associated Signaling Pathways
Peroxisomes intersect with several key longevity-associated signaling pathways, including AMPK/SIRT1/PGC-1α, mTOR, Nrf2, and FOXO3 [167,168,169,170,171]. Through these signaling axes, they contribute to the coordination of metabolic adaptations, stress resistance, and redox homeostasis. For example, activation of Nrf2 enhances the expression of catalase, a major peroxisomal antioxidant enzyme, thereby mitigating oxidative damage and preserving redox homeostasis [172]. Maintenance of peroxisomal health may therefore support cellular homeostasis, preserve mitochondrial function, and counteract age-related dysfunction across multiple tissues [173].
5.3. Preserving Peroxisomal Homeostasis During Aging
Strategies aimed at preserving or enhancing peroxisomal function during aging include promoting peroxisome biogenesis and protein import, fine-tuning selective autophagy of damaged peroxisomes, and maintaining balanced ROS signaling (Figure 3). Sustaining the molecular machinery responsible for peroxisome formation and enzyme import can help maintain organelle number and functionality with age. Likewise, appropriate regulation of pexophagy prevents the accumulation of dysfunctional peroxisomes, although both excessive and insufficient peroxisome turnover may have context-dependent deleterious effects [174,175]. Given the central role of peroxisomes in ROS metabolism, interventions that support ROS hormesis—preserving beneficial signaling while limiting oxidative damage—may be particularly effective in maintaining cellular function during aging.
Figure 3.
Potential interventions to preserve peroxisome function during cellular and organismal aging. For details, see the main text.
5.4. Pharmacological Modulation of Peroxisomal Pathways
Pharmacological interventions targeting peroxisomal pathways have shown promise in preclinical models [176]. Activation of peroxisome proliferator-activated receptors (PPARs), particularly PPARα, can restore peroxisomal activity, enhance fatty acid oxidation, and protect against age-associated metabolic disorders, including NAFLD, dyslipidemia, metabolic syndrome, and type 2 diabetes, in aging models [177,178,179,180,181,182,183]. However, the pleiotropic effects of PPAR signaling extend beyond peroxisome regulation and therefore warrant careful consideration [180].
Modulation of peroxisome biogenesis factors also represents a complementary strategy to enhance peroxisome abundance. For example, DHA induces peroxisome elongation through PEX11B oligomerization, a process that is prerequisite for peroxisome division [184]. In addition, certain small molecules and ligands can stabilize mutant PEX1, PEX6, or PEX12, thereby partially restoring peroxisomal matrix protein import, while defects in plasmalogen biosynthesis may be bypassed through plasmalogen replacement [185,186,187,188]. Collectively, these approaches alleviate cellular stress by restoring or circumventing key peroxisomal metabolic functions, including fatty acid β-oxidation and plasmalogen biosynthesis. Moreover, activation of the AMPK/SIRT1/PGC-1α signaling pathway, either pharmacologically or through caloric restriction, is likely to enhance peroxisome biogenesis, stimulate fatty acid oxidation, and limit the accumulation of damaged peroxisomes, thereby reinforcing longevity-associated stress-response pathways [170,189].
5.5. Lifestyle Interventions and Systemic Modulators of Peroxisomal Function
Lifestyle interventions and pharmacological agents—including caloric restriction, physical exercise, and compounds such as fibrate drugs, resveratrol, and rapamycin—have demonstrated, either directly or indirectly, potential to restore peroxisomal homeostasis and support healthy aging in model systems [79,80,170,190,191,192,193,194,195,196,197,198]. These interventions may fine-tune peroxisome abundance, redox balance, and organelle turnover by engaging conserved nutrient- and energy-sensing pathways. Nevertheless, given the pleiotropic nature of many small-molecule interventions, potential off-target effects and context-dependent outcomes require careful evaluation.
5.6. Future Directions: Peroxisome-Targeted Strategies for Healthy Aging
Overall, targeting peroxisomes represents a promising yet still largely experimental strategy to promote healthy aging. By preserving lipid and ROS metabolism, maintaining mitochondrial health, and modulating conserved longevity pathways, peroxisome-targeted interventions may mitigate age-associated metabolic and neurodegenerative disorders. While current evidence is predominantly derived from preclinical studies, future research should determine whether peroxisome-targeted strategies can meaningfully improve healthspan and lifespan in humans.
6. Conclusions
Peroxisomes are increasingly recognized as underappreciated regulators of aging that influence cellular resilience and systemic metabolism. As peroxisomal dysfunction has been implicated in various age-related disorders, a deeper understanding of peroxisomal biology—including organelle biogenesis, metabolic and signaling functions, and pexophagy—is essential to elucidate how these organelles safeguard healthy aging and contribute to age-associated disease. Although targeting peroxisomes represents a promising therapeutic avenue, strategies aimed at modulating peroxisomal function as anti-aging interventions remain in their infancy, underscoring the need for further mechanistic and translational research.
Acknowledgments
During the preparation of this manuscript, the authors used ChatGPT (https://chatgpt.com/; accessed 1 October 2025–22 January 2026; GPT-4, OpenAI, San Francisco, CA, USA) and Perplexity AI (https://www.perplexity.ai/; accessed 16–19 December 2025; powered by the Sonar model, San Francisco, CA, USA) to assist with text structuring. All content was reviewed, edited, and verified by the authors for accuracy. The authors also acknowledge BioRender (https://biorender.com; accessed on 22 December 2025) for providing figure templates, from which some elements were incorporated into the figures.
Abbreviations
The following abbreviations are used in this manuscript:
| AD | Alzheimer’s disease |
| ALS | Amyotrophic lateral sclerosis |
| AMPK | 5′-AMP-activated protein kinase catalytic subunit alpha-1 |
| A-T | Ataxia-telangiectasia |
| DHA | Docosahexaenoic acid |
| ER | Endoplasmic reticulum |
| HGPS | Hutchinson-Gilford progeria syndrome |
| MS | Multiple sclerosis |
| mTOR | Mammalian target of rapamycin |
| MUFA | Mono-unsaturated fatty acid |
| NAFLD | Nonalcoholic fatty liver disease |
| PD | Parkinson’s disease |
| PEX | Peroxin |
| PMP | Peroxisomal membrane protein |
| PPAR | Peroxisome proliferator-activated receptor |
| PTS | Peroxisomal targeting signal |
| PUFA | Poly-unsaturated fatty acid |
| ROS | Reactive oxygen species |
| SIRT1 | NAD-dependent protein deacetylase sirtuin-1 |
| VLCFA | Very-long-chain fatty acid |
Author Contributions
Conceptualization, M.F.; writing—original draft preparation, A.V., M.Z., R.C. and M.F.; writing—review and editing, A.V., C.L. and M.F.; visualization, A.V., C.L. and M.F.; project administration, M.F.; funding acquisition, M.F. All authors have read and agreed to the published version of the manuscript.
Institutional Review Board Statement
Not applicable.
Informed Consent Statement
Not applicable.
Data Availability Statement
All information in this review is derived from published literature cited in the manuscript; no new data were generated or analyzed, and data sharing is therefore not applicable.
Conflicts of Interest
The authors declare no conflicts of interest. The funders had no role in the study design; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.
Funding Statement
The APC was funded by the Bijzonder Onderzoeksfonds of KU Leuven (C14/25/132).
Footnotes
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
References
- 1.Dodig S., Čepelak I., Pavić I. Hallmarks of Senescence and Aging. Biochem. Med. 2019;29:030501. doi: 10.11613/BM.2019.030501. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Palmer A.K., Jensen M.D. Metabolic Changes in Aging Humans: Current Evidence and Therapeutic Strategies. J. Clin. Investig. 2022;132:e158451. doi: 10.1172/JCI158451. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Gonzales M.M., Garbarino V.R., Pollet E., Palavicini J.P., Kellogg D.L., Kraig E., Orr M.E. Biological Aging Processes Underlying Cognitive Decline and Neurodegenerative Disease. J. Clin. Investig. 2022;132:e158453. doi: 10.1172/JCI158453. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.García-Domínguez M. Pathological and Inflammatory Consequences of Aging. Biomolecules. 2025;15:404. doi: 10.3390/biom15030404. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Martel J., Ojcius D.M., Young J.D. Lifestyle Interventions to Delay Senescence. Biomed. J. 2024;47:100676. doi: 10.1016/j.bj.2023.100676. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Behrenbruch N., Schwarck S., Schumann-Werner B., Molloy E.N., Garcia-Garcia B., Hochkeppler A., Fischer L., Büchel A.T., Incesoy E.I., Bernal J., et al. Physically and Mentally Active Lifestyle Relates to Younger Brain and Cognitive Age. GeroScience. 2025. in press . [DOI] [PMC free article] [PubMed]
- 7.López-Otín C., Blasco M.A., Partridge L., Serrano M., Kroemer G. Hallmarks of Aging: An Expanding Universe. Cell. 2023;186:243–278. doi: 10.1016/j.cell.2022.11.001. [DOI] [PubMed] [Google Scholar]
- 8.Novikoff A.B., Novikoff P.M., Davis C., Quintana N. Studies on Microperoxisomes. V. Are Microperoxisomes Ubiquitous in mammalian cells? J. Histochem. Cytochem. 1973;21:737–755. doi: 10.1177/21.8.737. [DOI] [PubMed] [Google Scholar]
- 9.Moras M., Lefevre S.D., Ostuni M.A. From Erythroblasts to Mature Red Blood Cells: Organelle Clearance in Mammals. Front. Physiol. 2017;8:1076. doi: 10.3389/fphys.2017.01076. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Nenicu A., Lüers G.H., Kovacs W., David M., Zimmer A., Bergmann M., Baumgart-Vogt E. Peroxisomes in Human and Mouse Testis: Differential Expression of Peroxisomal Proteins in Germ Cells and Distinct Somatic Cell Types of the Testis. Biol. Reprod. 2007;77:1060–1072. doi: 10.1095/biolreprod.107.061242. [DOI] [PubMed] [Google Scholar]
- 11.Costello M.J., Brennan L.A., Basu S., Chauss D., Mohamed A., Gilliland K.O., Johnsen S., Menko S., Kantorow M. Autophagy and Mitophagy Participate in Ocular Lens Organelle Degradation. Exp. Eye Res. 2013;116:141–150. doi: 10.1016/j.exer.2013.08.017. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Fransen M., Lismont C. Redox Signaling from and to Peroxisomes: Progress, Challenges, and Prospects. Antioxid. Redox Signal. 2019;30:95–112. doi: 10.1089/ars.2018.7515. [DOI] [PubMed] [Google Scholar]
- 13.Wanders R.J.A., Baes M., Ribeiro D., Ferdinandusse S., Waterham H.R. The Physiological Functions of Human Peroxisomes. Physiol. Rev. 2023;103:957–1024. doi: 10.1152/physrev.00051.2021. [DOI] [PubMed] [Google Scholar]
- 14.Van Veldhoven P.P. Biochemistry and Genetics of Inherited Disorders of Peroxisomal Fatty Acid Metabolism. J. Lipid Res. 2010;51:2863–2895. doi: 10.1194/jlr.R005959. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Dorninger F., Werner E.R., Berger J., Watschinger K. Regulation of Plasmalogen Metabolism and Traffic in Mammals: The Fog Begins to Lift. Front. Cell Dev. Biol. 2022;10:946393. doi: 10.3389/fcell.2022.946393. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Ferdinandusse S., Denis S., Mooijer P.A., Zhang Z., Reddy J.K., Spector A.A., Wanders R.J. Identification of the Peroxisomal Beta-Oxidation Enzymes Involved in the Biosynthesis of Docosahexaenoic Acid. J. Lipid Res. 2001;42:1987–1995. doi: 10.1016/S0022-2275(20)31527-3. [DOI] [PubMed] [Google Scholar]
- 17.Lismont C., Revenco I., Fransen M. Peroxisomal Hydrogen Peroxide Metabolism and Signaling in Health and Disease. Int. J. Mol. Sci. 2019;20:3673. doi: 10.3390/ijms20153673. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Yamada J., Ogawa S., Horie S., Watanabe T., Suga T. Participation of Peroxisomes in the Metabolism of Xenobiotic Acyl Compounds: Comparison between Peroxisomal and Mitochondrial Beta-Oxidation of Omega-Phenyl Fatty Acids in Rat Liver. Biochim. Biophys. Acta. 1987;921:292–301. doi: 10.1016/0005-2760(87)90030-0. [DOI] [PubMed] [Google Scholar]
- 19.Kou J., Kovacs G.G., Höftberger R., Kulik W., Brodde A., Forss-Petter S., Hönigschnabl S., Gleiss A., Brügger B., Wanders R., et al. Peroxisomal Alterations in Alzheimer’s Disease. Acta Neuropathol. 2011;122:271–283. doi: 10.1007/s00401-011-0836-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Cimini A., Moreno S., D’Amelio M., Cristiano L., D’Angelo B., Falone S., Benedetti E., Carrara P., Fanelli F., Cecconi F., et al. Early Biochemical and Morphological Modifications in the Brain of a Transgenic Mouse Model of Alzheimer’s Disease: A Role for Peroxisomes. J. Alzheimers Dis. 2009;18:935–952. doi: 10.3233/JAD-2009-1199. [DOI] [PubMed] [Google Scholar]
- 21.Fransen M., Lismont C., Walton P. The Peroxisome-Mitochondria Connection: How and Why? Int. J. Mol. Sci. 2017;18:1126. doi: 10.3390/ijms18061126. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Schrader M., Kamoshita M., Islinger M. Organelle Interplay-Peroxisome Interactions in Health and Disease. J. Inherit. Metab. Dis. 2020;43:71–89. doi: 10.1002/jimd.12083. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.DiGiovanni L.F., Khroud P.K., Carmichael R.E., Schrader T.A., Gill S.K., Germain K., Jomphe R.Y., Wiesinger C., Boutry M., Kamoshita M., et al. ROS Transfer at Peroxisome-Mitochondria Contact Regulates Mitochondrial Redox. Science. 2025;389:157–162. doi: 10.1126/science.adn2804. [DOI] [PubMed] [Google Scholar]
- 24.Kim H.Y., Huang B.X., Spector A.A. Molecular and Signaling Mechanisms for Docosahexaenoic Acid-Derived Neurodevelopment and Neuroprotection. Int. J. Mol. Sci. 2022;23:4635. doi: 10.3390/ijms23094635. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Scalabrin M., Turco E., Davigo I., Filadi R., Nogara L., Gherardi G., Barazzuol L., Armani A., Trani G., Negro S., et al. Alterations in Peroxisome-Mitochondria Interplay in Skeletal Muscle Accelerate Muscle Dysfunction. Nat. Commun. 2025;16:9868. doi: 10.1038/s41467-025-64833-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Kim J., Bai H. Peroxisomal Stress Response and Inter-Organelle Communication in Cellular Homeostasis and Aging. Antioxidants. 2022;11:192. doi: 10.3390/antiox11020192. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Fransen M., Nordgren M., Wang B., Apanasets O., Van Veldhoven P.P. Aging, Age-Related Diseases and Peroxisomes. Subcell. Biochem. 2013;69:45–65. doi: 10.1007/978-94-007-6889-5_3. [DOI] [PubMed] [Google Scholar]
- 28.Waterham H.R., Ferdinandusse S., Wanders R.J. Human Disorders of Peroxisome Metabolism and Biogenesis. Biochim. Biophys. Acta. 2016;1863:922–933. doi: 10.1016/j.bbamcr.2015.11.015. [DOI] [PubMed] [Google Scholar]
- 29.Cipolla C.M., Lodhi I.J. Peroxisomal Dysfunction in Age-Related Diseases. Trends Endocrinol. Metab. 2017;28:297–308. doi: 10.1016/j.tem.2016.12.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Uzor N.E., McCullough L.D., Tsvetkov A.S. Peroxisomal Dysfunction in Neurological Diseases and Brain Aging. Front. Cell Neurosci. 2020;14:44. doi: 10.3389/fncel.2020.00044. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Périchon R., Bourre J.M. Peroxisomal Beta-Oxidation Activity and Catalase Activity During Development and Aging in Mouse Liver. Biochimie. 1995;77:288–293. doi: 10.1016/0300-9084(96)88138-7. [DOI] [PubMed] [Google Scholar]
- 32.Legakis J.E., Koepke J.I., Jedeszko C., Barlaskar F., Terlecky L.J., Edwards H.J., Walton P.A., Terlecky S.R. Peroxisome Senescence in Human Fibroblasts. Mol. Biol. Cell. 2002;13:4243–4255. doi: 10.1091/mbc.e02-06-0322. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Mi J., Garcia-Arcos I., Alvarez R., Cristobal S. Age-Related Subproteomic Analysis of Mouse Liver and Kidney Peroxisomes. Proteome Sci. 2007;5:19. doi: 10.1186/1477-5956-5-19. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Correia J., Sinha Roy P., Holden K.G., Kohut M.L., Bai H. Aging Impairs Peroxisome Biogenesis in Human B Cells. J. Gerontol. A Biol. Sci. Med. Sci. 2025;81:glaf148. doi: 10.1093/gerona/glaf148. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Kim P.K., Mullen R.T., Schumann U., Lippincott-Schwartz J. The Origin and Maintenance of Mammalian Peroxisomes Involves a De Novo PEX16-Dependent Pathway from the ER. J. Cell Biol. 2006;173:521–532. doi: 10.1083/jcb.200601036. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Sugiura A., Mattie S., Prudent J., McBride H.M. Newly Born Peroxisomes Are a Hybrid of Mitochondrial and ER-Derived Pre-Peroxisomes. Nature. 2017;542:251–254. doi: 10.1038/nature21375. [DOI] [PubMed] [Google Scholar]
- 37.Carmichael R.E., Islinger M., Schrader M. Fission Impossible (?)-New Insights into Disorders of Peroxisome Dynamics. Cells. 2022;11:1922. doi: 10.3390/cells11121922. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Distel B., Erdmann R., Gould S.J., Blobel G., Crane D.I., Cregg J.M., Dodt G., Fujiki Y., Goodman J.M., Just W.W., et al. A Unified Nomenclature for Peroxisome Biogenesis Factors. J. Cell Biol. 1996;135:1–3. doi: 10.1083/jcb.135.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Verhoeven N., Oshima Y., Cartier E., Bippes C.C., Neutzner A., Boyman L., Karbowski M. Outer Mitochondrial Membrane E3 Ub Ligase MARCH5 Controls De Novo Peroxisome Biogenesis. Dev. Cell. 2025;60:40–50.e5. doi: 10.1016/j.devcel.2024.09.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Zheng J., Chen J., Cao Z., Wu K., Wang J., Guo Y., Zhuang M. Ubiquitin Ligase MARCH5 Controls the Formation of Mitochondria-Derived Pre-Peroxisomes. Dev. Cell. 2025;60:30–39.e3. doi: 10.1016/j.devcel.2024.09.029. [DOI] [PubMed] [Google Scholar]
- 41.Jones J.M., Morrell J.C., Gould S.J. PEX19 is a Predominantly Cytosolic Chaperone and Import Receptor for Class 1 Peroxisomal Membrane Proteins. J. Cell Biol. 2004;164:57–67. doi: 10.1083/jcb.200304111. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Barros-Barbosa A., Rodrigues T.A., Ferreira M.J., Pedrosa A.G., Teixeira N.R., Francisco T., Azevedo J.E. The Intrinsically Disordered Nature of the Peroxisomal Protein Translocation Machinery. FEBS J. 2019;286:24–38. doi: 10.1111/febs.14704. [DOI] [PubMed] [Google Scholar]
- 43.Carvalho A.F., Pinto M.P., Grou C.P., Alencastre I.S., Fransen M., Sá-Miranda C., Azevedo J.E. Ubiquitination of Mammalian Pex5p, the Peroxisomal Import Receptor. J. Biol. Chem. 2007;282:31267–31272. doi: 10.1074/jbc.M706325200. [DOI] [PubMed] [Google Scholar]
- 44.Feng P., Wu X., Erramilli S.K., Paulo J.A., Knejski P., Gygi S.P., Kossiakoff A.A., Rapoport T.A. A Peroxisomal Ubiquitin Ligase Complex Forms a Retrotranslocation Channel. Nature. 2022;607:374–380. doi: 10.1038/s41586-022-04903-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Skowyra M.L., Feng P., Rapoport T.A. Towards Solving the Mystery of Peroxisomal Matrix Protein Import. Trends Cell Biol. 2024;34:388–405. doi: 10.1016/j.tcb.2023.08.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Fujiki Y., Okumoto K., Honsho M., Abe Y. Molecular Insights into Peroxisome Homeostasis and Peroxisome Biogenesis Disorders. Biochim. Biophys. Acta Mol. Cell Res. 2022;1869:119330. doi: 10.1016/j.bbamcr.2022.119330. [DOI] [PubMed] [Google Scholar]
- 47.Apanasets O., Grou C.P., Van Veldhoven P.P., Brees C., Wang B., Nordgren M., Dodt G., Azevedo J.E., Fransen M. PEX5, the Shuttling Import Receptor for Peroxisomal Matrix Proteins, Is a Redox-Sensitive Protein. Traffic. 2014;15:94–103. doi: 10.1111/tra.12129. [DOI] [PubMed] [Google Scholar]
- 48.Narayan V., Ly T., Pourkarimi E., Murillo A.B., Gartner A., Lamond A.I., Kenyon C. Deep Proteome Analysis Identifies Age-Related Processes in C. elegans. Cell Syst. 2016;3:144–159. doi: 10.1016/j.cels.2016.06.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Huang K., Miao T., Chang K., Kim J., Kang P., Jiang Q., Simmonds A.J., Di Cara F., Bai H. Impaired Peroxisomal Import in Drosophila Oenocytes Causes Cardiac Dysfunction by Inducing Upd3 as a Peroxikine. Nat. Commun. 2020;11:2943. doi: 10.1038/s41467-020-16781-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Walton P.A., Brees C., Lismont C., Apanasets O., Fransen M. The Peroxisomal Import Receptor PEX5 Functions as a Stress Sensor, Retaining Catalase in the Cytosol in Times of Oxidative Stress. Biochim. Biophys. Acta Mol. Cell Res. 2017;1864:1833–1843. doi: 10.1016/j.bbamcr.2017.07.013. [DOI] [PubMed] [Google Scholar]
- 51.Guo X., Du G., Zhou J., Fu F., Yuan Y., Liu X., Chen H., Wan Q., Gong B., Chen H. Aging-Related Peroxisomal Dysregulation Disrupts Intestinal Stem Cell Differentiation Through Alterations of Very Long-Chain Fatty Acid Oxidation. PLoS Biol. 2025;23:e3003552. doi: 10.1371/journal.pbio.3003552. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Sebastiani P., Federico A., Morris M., Gurinovich A., Tanaka T., Chandler K.B., Andersen S.L., Denis G., Costello C.E., Ferrucci L., et al. Protein Signatures of Centenarians and Their Offspring Suggest Centenarians Age Slower than Other Humans. Aging Cell. 2021;20:e13290. doi: 10.1111/acel.13290. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Li J., Wang W. Mechanisms and Functions of Pexophagy in Mammalian Cells. Cells. 2021;10:1094. doi: 10.3390/cells10051094. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Bajdzienko J., Bremm A. Mammalian Pexophagy at a Glance. J. Cell Sci. 2024;137:jcs259775. doi: 10.1242/jcs.259775. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55.Wei X., Manandhar L., Kim H., Chhetri A., Hwang J., Jang G., Park C., Park R. Pexophagy and Oxidative Stress: Focus on Peroxisomal Proteins and Reactive Oxygen Species (ROS) Signaling Pathways. Antioxidants. 2025;14:126. doi: 10.3390/antiox14020126. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Carosi J.M., Martin A., Hein L.K., Hassiotis S., Hattersley K.J., Turner B.J., Fourrier C., Bensalem J., Sargeant T.J. Autophagy Across Tissues of Aging Mice. PLoS ONE. 2025;20:e0325505. doi: 10.1371/journal.pone.0325505. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Liu G.Y., Sabatini D.M. mTOR at the Nexus of Nutrition, Growth, Ageing and Disease. Nat. Rev. Mol. Cell Biol. 2020;21:183–203. doi: 10.1038/s41580-019-0199-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Salminen A., Kaarniranta K. SIRT1: Regulation of Longevity via Autophagy. Cell Signal. 2009;21:1356–1360. doi: 10.1016/j.cellsig.2009.02.014. [DOI] [PubMed] [Google Scholar]
- 59.Penugurti V., Manne R.K., Bai L., Kant R., Lin H.K. AMPK: The Energy Sensor at the Crossroads of Aging and Cancer. Semin. Cancer Biol. 2024;106–107:15–27. doi: 10.1016/j.semcancer.2024.08.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60.Li Y., Tian X., Luo J., Bao T., Wang S., Wu X. Molecular Mechanisms of Aging and Anti-Aging Strategies. Cell Commun. Signal. 2024;22:285. doi: 10.1186/s12964-024-01663-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61.Di Carlo E., Sorrentino C. Oxidative Stress and Age-Related Tumors. Antioxidants. 2024;13:1109. doi: 10.3390/antiox13091109. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62.Dolese D.A., Junot M.P., Ghosh B., Butsch T.J., Johnson A.E., Bohnert K.A. Degradative Tubular Lysosomes Link Pexophagy to Starvation and Early Aging in C. elegans. Autophagy. 2022;18:1522–1533. doi: 10.1080/15548627.2021.1990647. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63.Barone F.G., Marcello M., Urbé S., Sanchez-Soriano N., Clague M.J. Whole Organism and Tissue-Specific Analysis of Pexophagy in Drosophila. Open Biol. 2025;15:240291. doi: 10.1098/rsob.240291. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 64.Xiong Y., Gao W., Wu Z., Ding R., Ma H., Zheng J., Li B., Sang Y., Zhang L., Gong W., et al. In Vivo Mapping of Peroxisome Dynamics and Pexophagy Using PO-TRG and CA-PO-TRG Reporter Mice. J. Cell. Biol. 2026;225:e202503169. doi: 10.1083/jcb.202503169. [DOI] [PubMed] [Google Scholar]
- 65.Iwata J., Ezaki J., Komatsu M., Yokota S., Ueno T., Tanida I., Chiba T., Tanaka K., Kominami E. Excess Peroxisomes Are Degraded by Autophagic Machinery in Mammals. J. Biol. Chem. 2006;281:4035–4041. doi: 10.1074/jbc.M512283200. [DOI] [PubMed] [Google Scholar]
- 66.Houri K., Mori T., Onodera Y., Tsujimoto T., Takehara T., Nakao S., Teramura T., Fukuda K. miR-142 Induces Accumulation of Reactive Oxygen Species (ROS) by Inhibiting Pexophagy in Aged Bone Marrow Mesenchymal Stem Cells. Sci. Rep. 2020;10:3735. doi: 10.1038/s41598-020-60346-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67.Fransen M., Lismont C. Peroxisomal Hydrogen Peroxide Signaling: A New Chapter in Intracellular Communication Research. Curr. Opin. Chem. Biol. 2024;78:102426. doi: 10.1016/j.cbpa.2024.102426. [DOI] [PubMed] [Google Scholar]
- 68.Nandi A., Yan L.J., Jana C.K., Das N. Role of Catalase in Oxidative Stress- and Age-Associated Degenerative Diseases. Oxid. Med. Cell. Longev. 2019;2019:9613090. doi: 10.1155/2019/9613090. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 69.Costa C.F., Lismont C., Anteghini M., Revenco I., Li H., Fransen M. The Mystery Behind Hydrogen Peroxide Permeation Across the Peroxisomal Membrane. In: Bienert A., Sitia R., Medrano I., editors. Peroxiporins: Redox Signal Mediators in and Between Cells. 1st ed. CRC Press; Boca Raton, FL, USA: Taylor & Francis; Abingdon, UK: pp. 88–101. [DOI] [Google Scholar]
- 70.Sies H., Belousov V.V., Chandel N.S., Davies M.J., Jones D.P., Mann G.E., Murphy M.P., Yamamoto M., Winterbourn C. Defining Roles of Specific Reactive Oxygen Species (ROS) in Cell Biology and Physiology. Nat. Rev. Mol. Cell Biol. 2022;23:499–515. doi: 10.1038/s41580-022-00456-z. [DOI] [PubMed] [Google Scholar]
- 71.Yang L., Zhang Y., Wang S., Zhang W., Shi R. Decreased Liver Peroxisomal Beta-Oxidation Accompanied by Changes in Brain Fatty Acid Composition in Aged Rats. Neurol. Sci. 2014;35:289–293. doi: 10.1007/s10072-013-1509-3. [DOI] [PubMed] [Google Scholar]
- 72.Gu J., Chen L., Sun R., Wang J.L., Wang J., Lin Y., Lei S., Zhang Y., Lv D., Jiang F., et al. Plasmalogens Eliminate Aging-Associated Synaptic Defects and Microglia-Mediated Neuroinflammation in Mice. Front. Mol. Biosci. 2022;9:815320. doi: 10.3389/fmolb.2022.815320. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 73.Perino A., Demagny H., Velazquez-Villegas L., Schoonjans K. Molecular Physiology of Bile Acid Signaling in Health, Disease, and Aging. Physiol. Rev. 2021;101:683–731. doi: 10.1152/physrev.00049.2019. [DOI] [PubMed] [Google Scholar]
- 74.Weiser M.J., Butt C.M., Mohajeri M.H. Docosahexaenoic Acid and Cognition throughout the Lifespan. Nutrients. 2016;8:99. doi: 10.3390/nu8020099. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 75.Lukiw W.J., Bazan N.G. Docosahexaenoic Acid and the Aging Brain. J. Nutr. 2008;138:2510–2514. doi: 10.3945/jn.108.096016. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 76.Das U.N. “Cell Membrane Theory of Senescence” and the Role of Bioactive Lipids in Aging, and Aging-Associated Diseases and Their Therapeutic Implications. Biomolecules. 2021;11:241. doi: 10.3390/biom11020241. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 77.Akl M.G., Fawzy E., Deif M., Farouk A., Elshorbagy A.K. Perturbed Adipose Tissue Hydrogen Peroxide Metabolism in Centrally Obese Men: Association with Insulin Resistance. PLoS ONE. 2017;12:e0177268. doi: 10.1371/journal.pone.0177268. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 78.Huang T.Y., Zheng D., Hickner R.C., Brault J.J., Cortright R.N. Peroxisomal Gene and Protein Expression Increase in Response to a High-Lipid Challenge in Human Skeletal Muscle. Metabolism. 2019;98:53–61. doi: 10.1016/j.metabol.2019.06.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 79.Jiang S., Uddin M.J., Yu X., Piao L., Dorotea D., Oh G.T., Ha H. Peroxisomal Fitness: A Potential Protective Mechanism of Fenofibrate against High Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Mice. Diabetes Metab. J. 2022;46:829–842. doi: 10.4093/dmj.2021.0274. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 80.Russell A.P., Feilchenfeldt J., Schreiber S., Praz M., Crettenand A., Gobelet C., Meier C.A., Bell D.R., Kralli A., Giacobino J.P., et al. Endurance Training in Humans Leads to Fiber Type-Specific Increases in Levels of Peroxisome Proliferator-Activated Receptor-Gamma Coactivator-1 and Peroxisome Proliferator-Activated Receptor-Alpha in Skeletal Muscle. Diabetes. 2003;52:2874–2881. doi: 10.2337/diabetes.52.12.2874. [DOI] [PubMed] [Google Scholar]
- 81.Ignatowicz E., Woźniak A., Kulza M., Seńczuk-Przybyłowska M., Cimino F., Piekoszewski W., Chuchracki M., Florek E. Exposure to Alcohol and Tobacco Smoke Causes Oxidative Stress in Rats. Pharmacol. Rep. 2013;65:906–913. doi: 10.1016/S1734-1140(13)71072-7. [DOI] [PubMed] [Google Scholar]
- 82.Matsushita M., Futawaka K., Hayashi M., Murakami K., Mitsutani M., Hatai M., Watamoto Y., Yoshikawa N., Nakamura K., Tagami T., et al. Cigarette Smoke Extract Modulates Functions of Peroxisome Proliferator-Activated Receptors. Biol. Pharm. Bull. 2019;42:1628–1636. doi: 10.1248/bpb.b18-00991. [DOI] [PubMed] [Google Scholar]
- 83.Zhang Y., Zhang W., Li Y., Yao H., Wang Y., Zhang X., Zeng J. Induction of Peroxisomal β-Oxidation as a Critical Mechanism for Ethanol-Induced Hepatic Triglyceride Accumulation. FASEB Bioadv. 2025;7:e70013. doi: 10.1096/fba.2024-00211. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 84.Lizard G., Rouaud O., Demarquoy J., Cherkaoui-Malki M., Iuliano L. Potential Roles of Peroxisomes in Alzheimer’s Disease and in Dementia of the Alzheimer’s Type. J. Alzheimer’s Dis. 2012;29:241–254. doi: 10.3233/JAD-2011-111163. [DOI] [PubMed] [Google Scholar]
- 85.Jo D.S., Park N.Y., Cho D.H. Peroxisome Quality Control and Dysregulated Lipid Metabolism in Neurodegenerative Diseases. Exp. Mol. Med. 2020;52:1486–1495. doi: 10.1038/s12276-020-00503-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 86.Roczkowsky A., Rachubinski R.A., Hobman T.C., Power C. Peroxisomes as Emerging Clinical Targets in Neuroinflammatory Diseases. Front. Mol. Neurosci. 2025;18:1642590. doi: 10.3389/fnmol.2025.1642590. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 87.Gao J., Vicuna L., Wang X. Organelle Abnormalities in Alzheimer’s Disease. Organelle. 2025;3:5. doi: 10.61747/0ifp.202503005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 88.Brodde A., Teigler A., Brugger B., Lehmann W.D., Wieland F., Berger J., Just W.W. Impaired Neurotransmission in Ether Lipid-Deficient Nerve Terminals. Hum. Mol. Genet. 2012;21:2713–2724. doi: 10.1093/hmg/dds097. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 89.Dorninger F., Forss-Petter S., Berger J. From Peroxisomal Disorders to Common Neurodegenerative Diseases—The Role of Ether Phospholipids in the Nervous System. FEBS Lett. 2017;591:2761–2788. doi: 10.1002/1873-3468.12788. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 90.Fujino T., Hossain M.S., Mawatari S. Therapeutic Efficacy of Plasmalogens for Alzheimer’s Disease, Mild Cognitive Impairment, and Parkinson’s Disease in Conjunction with a New Hypothesis for the Etiology of Alzheimer’s Disease. Adv. Exp. Med. Biol. 2020;1299:195–212. doi: 10.1007/978-3-030-60204-8_14. [DOI] [PubMed] [Google Scholar]
- 91.Hossain M.S., Mawatari S., Fujino T. Plasmalogens Inhibit Neuroinflammation and Promote Cognitive Function. Brain Res. Bull. 2023;192:56–61. doi: 10.1016/j.brainresbull.2022.11.005. [DOI] [PubMed] [Google Scholar]
- 92.Semikasev E., Ahlemeyer B., Acker T., Schänzer A., Baumgart-Vogt E. Rise and Fall of Peroxisomes during Alzheimer’s Disease: A Pilot Study in Human Brains. Acta Neuropathol. Commun. 2023;11:80. doi: 10.1186/s40478-023-01567-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 93.Han X. Lipid Alterations in the Earliest Clinically Recognizable Stage of Alzheimer’s Disease: Implication of the Role of Lipids in the Pathogenesis of Alzheimer’s disease. Curr. Alzheimer Res. 2005;2:65–77. doi: 10.2174/1567205052772786. [DOI] [PubMed] [Google Scholar]
- 94.Fabelo N., Martín V., Santpere G., Marín R., Torrent L., Ferrer I., Díaz M. Severe Alterations in Lipid Composition of Frontal Cortex Lipid Rafts from Parkinson’s Disease and Incidental Parkinson’s Disease. Mol. Med. 2011;17:1107–1118. doi: 10.2119/molmed.2011.00119. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 95.Chaturvedi R.K., Beal M.F. PPAR: A Therapeutic Target in Parkinson’s Disease. J. Neurochem. 2008;106:506–518. doi: 10.1111/j.1471-4159.2008.05388.x. [DOI] [PubMed] [Google Scholar]
- 96.Miville-Godbout E., Bourque M., Morissette M., Al-Sweidi S., Smith T., Mochizuki A., Senanayake V., Jayasinghe D., Wang L., Goodenowe D., et al. Plasmalogen Augmentation Reverses Striatal Dopamine Loss in MPTP Mice. PLoS ONE. 2016;11:e0151020. doi: 10.1371/journal.pone.0151020. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 97.Fujino T., Yamada T., Asada T., Tsuboi Y., Wakana C., Mawatari S., Kono S. Efficacy and Blood Plasmalogen Changes by Oral Administration of Plasmalogen in Patients with Mild Alzheimer’s Disease and Mild Cognitive Impairment: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial. eBioMedicine. 2017;17:199–205. doi: 10.1016/j.ebiom.2017.02.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 98.Hossain M.S., Mawatari S., Honsho M., Okauchi T., Fujino T. KIT-13, a Novel Plasmalogen Derivative, Attenuates Neuroinflammation and Amplifies Cognition. Front. Cell Dev. Biol. 2024;12:1443536. doi: 10.3389/fcell.2024.1443536. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 99.Galvagnion C. The Role of Lipids Interacting with α-Synuclein in the Pathogenesis of Parkinson’s Disease. J. Park. Dis. 2017;7:433–450. doi: 10.3233/JPD-171103. [DOI] [PubMed] [Google Scholar]
- 100.Hacioglu G., Seval-Celik Y., Tanriover G., Ozsoy O., Saka-Topcuoglu E., Balkan S., Agar A. Docosahexaenoic Acid Provides Protective Mechanism in Bilaterally MPTP-Lesioned Rat Model of Parkinson’s Disease. Folia Histochem. Cytobiol. 2012;50:228–238. doi: 10.5603/FHC.2012.0032. [DOI] [PubMed] [Google Scholar]
- 101.Chitre N.M., Wood B.J., Ray A., Moniri N.H., Murnane K.S. Docosahexaenoic Acid Protects Motor Function and Increases Dopamine Synthesis in a Rat Model of Parkinson’s Disease via Mechanisms Associated with Increased Protein Kinase Activity in the Striatum. Neuropharmacology. 2020;167:107976. doi: 10.1016/j.neuropharm.2020.107976. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 102.Kerdiles O., Mi-Mba M.-F.O.M., Coulombe K., Tremblay C., Émond V., Saint-Pierre M., Rouxel C., Berthiaume L., Julien P., Cicchetti F., et al. Additive Neurorestorative Effects of Exercise and Docosahexaenoic Acid Intake in a Mouse Model of Parkinson’s Disease. Neural Regen. Res. 2025;20:574–586. doi: 10.4103/NRR.NRR-D-23-00595. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 103.Cacabelos D., Ayala V., Granado-Serrano A.B., Jové M., Torres P., Boada J., Cabré R., Ramírez-Núñez O., Gonzalo H., Soler-Cantero A., et al. Interplay Between TDP-43 and Docosahexaenoic Acid-related Processes in Amyotrophic Lateral Sclerosis. Neurobiol. Dis. 2016;88:148–160. doi: 10.1016/j.nbd.2016.01.007. [DOI] [PubMed] [Google Scholar]
- 104.Ramírez-Nuñez O., Jové M., Torres P., Sol J., Fontdevila L., Romero-Guevara R., Andrés-Benito P., Ayala V., Rossi C., Boada J., et al. Nuclear Lipidome Is Altered in Amyotrophic Lateral Sclerosis: A Pilot Study. J. Neurochem. 2021;158:482–499. doi: 10.1111/jnc.15373. [DOI] [PubMed] [Google Scholar]
- 105.Mitchell J., Paul P., Chen H.J., Morris A., Payling M., Falchi M., Habgood J., Panoutsou S., Winkler S., Tisato V., et al. Amyotrophic Lateral Sclerosis is Associated with a Mutation in D-Amino Acid Oxidase. Proc. Natl. Acad. Sci. USA. 2010;107:7556–7561. doi: 10.1073/pnas.0914128107. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 106.Lodhi I.J., Semenkovich C.F. Peroxisomes: A Nexus for Lipid Metabolism and Cellular Signaling. Cell Metab. 2014;19:380–392. doi: 10.1016/j.cmet.2014.01.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 107.He A., Chen X., Tan M., Chen Y., Lu D., Zhang X., Dean J.M., Razani B., Lodhi I.J. Acetyl-CoA Derived from Hepatic Peroxisomal β-Oxidation Inhibits Autophagy and Promotes Steatosis via mTORC1 Activation. Mol. Cell. 2020;79:30–42.e4. doi: 10.1016/j.molcel.2020.05.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 108.Ding L., Sun W., Balaz M., He A., Klug M., Wieland S., Caiazzo R., Raverdy V., Pattou F., Lefebvre P., et al. Peroxisomal β-oxidation Acts as a Sensor for Intracellular Fatty Acids and Regulates Lipolysis. Nat. Metab. 2021;3:1648–1661. doi: 10.1038/s42255-021-00489-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 109.Kleiboeker B., Lodhi I.J. Peroxisomal Regulation of Energy Homeostasis: Effect on Obesity and Related Metabolic Disorders. Mol. Metab. 2022;65:101577. doi: 10.1016/j.molmet.2022.101577. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 110.Klouwer F.C., Berendse K., Ferdinandusse S., Wanders R.J., Engelen M., Poll-The B.T. Zellweger Spectrum Disorders: Clinical Overview and Management Approach. Orphanet. J. Rare Dis. 2015;10:151. doi: 10.1186/s13023-015-0368-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 111.Liu J., Lu W., Shi B., Klein S., Su X. Peroxisomal Regulation of Redox Homeostasis and Adipocyte Metabolism. Redox Biol. 2019;24:101167. doi: 10.1016/j.redox.2019.101167. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 112.Piao L., Dorotea D., Jiang S., Koh E.H., Oh G.T., Ha H. Impaired Peroxisomal Fitness in Obese Mice, a Vicious Cycle Exacerbating Adipocyte Dysfunction via Oxidative Stress. Antioxid. Redox Signal. 2019;31:1339–1351. doi: 10.1089/ars.2018.7614. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 113.Elsner M., Gehrmann W., Lenzen S. Peroxisome-Generated Hydrogen Peroxide as Important Mediator of Lipotoxicity in Insulin-Producing Cells. Diabetes. 2011;60:200–208. doi: 10.2337/db09-1401. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 114.Akhrarova N., Saatov T., Salimova M., Khamraeva M., Zaynutdinov B., Shamansurova Z. Plasmalogen Levels are Associated with the Severity of Diabetic Neuropathy. Endocr. Abstr. 2022;81:EP456. doi: 10.1530/endoabs.81.EP456. [DOI] [Google Scholar]
- 115.Baboota R.K., Shinde A.B., Lemaire K., Fransen M., Vinckier S., Van Veldhoven P.P., Schuit F., Baes M. Functional Peroxisomes Are Required for β-cell Integrity in Mice. Mol. Metab. 2019;22:71–83. doi: 10.1016/j.molmet.2019.02.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 116.Guan H., Guo Y., Zhu L., Jiao Y., Liu X. Peroxisome Deficiency Dysregulates Fatty Acid Oxidization and Exacerbates Lipotoxicity in β Cells. Oxid. Med. Cell. Longev. 2021;2021:7726058. doi: 10.1155/2021/7726058. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 117.Hwang I., Lee J., Huh J.Y., Park J., Lee H.B., Ho Y.S., Ha H. Catalase Deficiency Accelerates Diabetic Renal Injury Through Peroxisomal Dysfunction. Diabetes. 2012;61:728–738. doi: 10.2337/db11-0584. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 118.Beyene H.B., Olshansky G.T., Smith A.A., Giles C., Huynh K., Cinel M., Mellett N.A., Cadby G., Hung J., Hui J., et al. High-Coverage Plasma Lipidomics Reveals Novel Sex-Specific Lipidomic Fingerprints of Age and BMI: Evidence from Two Large Population Cohort Studies. PLoS Biol. 2020;18:e3001049. doi: 10.1371/journal.pbio.3001049. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 119.Schooneveldt Y.L., Paul S., Huynh K., Beyene H.B., Mellett N.A., Watts G.F., Hung J., Hui J., Beilby J., Blangero J., et al. Alterations in Ether Lipid Metabolism in Obesity Revealed by Systems Genomics of Multi-omics Datasets. PLoS Biol. 2025;23:e3003349. doi: 10.1371/journal.pbio.3003349. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 120.Périchon R., Bourre J.M. Aging-Related Decrease in Liver Peroxisomal Fatty Acid Oxidation in Control and Clofibrate-Treated Mice. A Biochemical Study and Mechanistic Approach. Mech. Ageing Dev. 1996;87:115–126. doi: 10.1016/0047-6374(96)01705-8. [DOI] [PubMed] [Google Scholar]
- 121.Petkovic M., O’Brien C.E., Jan Y.N. Interorganelle Communication, Aging, and Neurodegeneration. Genes Dev. 2021;35:449–469. doi: 10.1101/gad.346759.120. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 122.Sharma A., Mistry M., Yao P., Liang Y., Hui S., Mair W.B. Peroxisomal Dysfunction Drives Loss of Dynamic Nutrient Responses to Initiate Metabolic Inflexibility During Aging. bioRxiv. 2025 doi: 10.1101/2025.02.14.638340. [DOI] [Google Scholar]
- 123.Smith R.L., Soeters M.R., Wüst R.C.I., Houtkooper R.H. Metabolic Flexibility as an Adaptation to Energy Resources and Requirements in Health and Disease. Endocr. Rev. 2018;39:489–517. doi: 10.1210/er.2017-00211. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 124.Khalaf F., Barayan D., Saldanha S., Jeschke M.G. Metabolaging: A New Geroscience Perspective Linking Aging Pathologies and Metabolic Dysfunction. Metabolism. 2025;166:156158. doi: 10.1016/j.metabol.2025.156158. [DOI] [PubMed] [Google Scholar]
- 125.Jo D.S., Cho D.H. Peroxisomal Dysfunction in Neurodegenerative Diseases. Arch. Pharm. Res. 2019;42:393–406. doi: 10.1007/s12272-019-01131-2. [DOI] [PubMed] [Google Scholar]
- 126.Pratama A.M., Sharma M., Naidu S., Bömmel H., Prabhuswamimath S.C., Madhusudhan T., Wihadmadyatami H., Bachhuka A., Karnati S. Peroxisomes and PPARs: Emerging Role as Master Regulators of Cancer Metabolism. Mol. Metab. 2024;90:102044. doi: 10.1016/j.molmet.2024.102044. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 127.Giordano C.R., Terlecky S.R. Peroxisomes, Cell Senescence, and Rates of Aging. Biochim. Biophys. Acta. 2012;1822:1358–1362. doi: 10.1016/j.bbadis.2012.03.013. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 128.Bozelli J.C., Epand R.M. DGKα, Bridging Membrane Shape Changes with Specific Molecular Species of DAG/PA: Implications in Cancer and Immunosurveillance. Cancers. 2022;14:5259. doi: 10.3390/cancers14215259. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 129.Sarkar C., Lipinski M.M. Role and Function of Peroxisomes in Neuroinflammation. Cells. 2024;13:1655. doi: 10.3390/cells13191655. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 130.Di Cara F., Andreoletti P., Trompier D., Vejux A., Bülow M.H., Sellin J., Lizard G., Cherkaoui-Malki M., Savary S. Peroxisomes in Immune Response and Inflammation. Int. J. Mol. Sci. 2019;20:3877. doi: 10.3390/ijms20163877. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 131.Terlecky S.R., Terlecky L.J., Giordano C.R. Peroxisomes, Oxidative Stress, and Inflammation. World J. Biol. Chem. 2012;3:93–97. doi: 10.4331/wjbc.v3.i5.93. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 132.Singh J., Khan M., Singh I. Silencing of Abcd1 and Abcd2 Genes Sensitizes Astrocytes for Inflammation: Implication for X-Adrenoleukodystrophy. J. Lipid Res. 2009;50:135–147. doi: 10.1194/jlr.M800321-JLR200. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 133.Chen P.M., Huang Y.H., Chen H.H., Chu P.Y. Catalase Expression Is an Independent Prognostic Marker in Lung Adenocarcinoma. Anticancer Res. 2024;44:287–300. doi: 10.21873/anticanres.16811. [DOI] [PubMed] [Google Scholar]
- 134.Glorieux C., Buc Calderon P. Targeting Catalase in Cancer. Redox Biol. 2024;77:103404. doi: 10.1016/j.redox.2024.103404. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 135.Dahabieh M.S., Di Pietro E., Jangal M., Goncalves C., Witcher M., Braverman N.E., Del Rincón S.V. Peroxisomes and Cancer: The Role of a Metabolic Specialist in a Disease of Aberrant Metabolism. Biochim. Biophys. Acta Rev. Cancer. 2018;1870:103–121. doi: 10.1016/j.bbcan.2018.07.004. [DOI] [PubMed] [Google Scholar]
- 136.Kim J.A. Peroxisome Metabolism in Cancer. Cells. 2020;9:1692. doi: 10.3390/cells9071692. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 137.Hussein M.A.F., Lismont C., Li H., Chai R., Claessens F., Fransen M. Peroxisomal Alterations in Prostate Cancer: Metabolic Shifts and Clinical Relevance. Cancers. 2025;17:2243. doi: 10.3390/cancers17132243. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 138.Diczfalusy U. β-Oxidation of Eicosanoids. Prog. Lipid Res. 1994;33:403–428. doi: 10.1016/0163-7827(94)90025-6. [DOI] [PubMed] [Google Scholar]
- 139.Sprecher H. The Roles of Anabolic and Catabolic Reactions in the Synthesis and Recycling of Polyunsaturated Fatty Acids. Prostaglandins Leukot. Essent. Fatty Acids. 2002;67:79–83. doi: 10.1054/plef.2002.0402. [DOI] [PubMed] [Google Scholar]
- 140.Das U.N. Lipoxins, Resolvins, Protectins, Maresins, and Nitrolipids: Connecting Lipids, Inflammation, and Cardiovascular Disease Risk. Curr. Cardiol. Risk Rep. 2010;4:24–31. doi: 10.1007/s12170-009-0068-x. [DOI] [Google Scholar]
- 141.Paintlia M.K., Paintlia A.S., Contreras M.A., Singh I., Singh A.K. Lipopolysaccharide-Induced Peroxisomal Dysfunction Exacerbates Cerebral White Matter Injury: Attenuation by N-Acetyl Cysteine. Exp. Neurol. 2008;210:560–576. doi: 10.1016/j.expneurol.2007.12.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 142.Dobson R., Giovannoni G. Multiple Sclerosis—A Review. Eur. J. Neurol. 2019;26:27–40. doi: 10.1111/ene.13819. [DOI] [PubMed] [Google Scholar]
- 143.Zarrouk A., Nury T., El Hajj H.I., Gondcaille C., Andreoletti P., Moreau T., Cherkaoui-Malki M., Berger J., Hammami M., Lizard G., et al. Potential Involvement of Peroxisome in Multiple Sclerosis and Alzheimer’s Disease: Peroxisome and Neurodegeneration. Adv. Exp. Med. Biol. 2020;1299:91–104. doi: 10.1007/978-3-030-60204-8_8. [DOI] [PubMed] [Google Scholar]
- 144.Bottelbergs A., Verheijden S., Van Veldhoven P.P., Just W., Devos R., Baes M. Peroxisome Deficiency but Not the Defect in Ether Lipid Synthesis Causes Activation of the Innate Immune System and Axonal Loss in the Central Nervous System. J. Neuroinflammation. 2012;9:61. doi: 10.1186/1742-2094-9-61. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 145.Singh I., Paintlia A.S., Khan M., Stanislaus R., Paintlia M.K., Haq E., Singh A.K., Contreras M.A. Impaired Peroxisomal Function in the Central Nervous System with Inflammatory Disease of Experimental Autoimmune Encephalomyelitis Animals and Protection by Lovastatin Treatment. Brain Res. 2004;1022:1–11. doi: 10.1016/j.brainres.2004.06.059. [DOI] [PubMed] [Google Scholar]
- 146.Gray E., Rice C., Hares K., Redondo J., Kemp K., Williams M., Brown A., Scolding N., Wilkins A. Reductions in Neuronal Peroxisomes in Multiple Sclerosis Grey Matter. Mult. Scler. 2014;20:651–659. doi: 10.1177/1352458513505691. [DOI] [PubMed] [Google Scholar]
- 147.Senanayake V.K., Jin W., Mochizuki A., Chitou B., Goodenowe D.B. Metabolic Dysfunctions in Multiple Sclerosis: Implications as to Causation, Early Detection, and Treatment, a Case Control Study. BMC Neurol. 2015;15:154. doi: 10.1186/s12883-015-0411-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 148.Schnabel F., Kornak U., Wollnik B. Premature Aging Disorders: A Clinical and Genetic Compendium. Clin. Genet. 2021;99:3–28. doi: 10.1111/cge.13837. [DOI] [PubMed] [Google Scholar]
- 149.Foo M.X.R., Ong P.F., Dreesen O. Premature Aging Syndromes: From Patients to Mechanism. J. Dermatol. Sci. 2019;96:58–65. doi: 10.1016/j.jdermsci.2019.10.003. [DOI] [PubMed] [Google Scholar]
- 150.Rieckher M., Garinis G.A., Schumacher B. Molecular Pathology of Rare Progeroid Diseases. Trends Mol. Med. 2021;27:907–922. doi: 10.1016/j.molmed.2021.06.011. [DOI] [PubMed] [Google Scholar]
- 151.Ahmed M.S., Ikram S., Bibi N., Mir A. Hutchinson–Gilford Progeria Syndrome: A Premature Aging Disease. Mol. Neurobiol. 2018;55:4417–4427. doi: 10.1007/s12035-017-0610-7. [DOI] [PubMed] [Google Scholar]
- 152.Mao X., Bharti P., Thaivalappil A., Cao K. Peroxisomal Abnormalities and Catalase Deficiency in Hutchinson–Gilford Progeria Syndrome. Aging. 2020;12:5195–5208. doi: 10.18632/aging.102941. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 153.Yan T., Li S., Jiang X., Oberley L.W. Altered Levels of Primary Antioxidant Enzymes in Progeria Skin Fibroblasts. Biochem. Biophys. Res. Commun. 1999;257:163–167. doi: 10.1006/bbrc.1999.0423. [DOI] [PubMed] [Google Scholar]
- 154.Rothblum-Oviatt C., Wright J., Lefton-Greif M.A., McGrath-Morrow S.A., Crawford T.O., Lederman H.M. Ataxia Telangiectasia: A Review. Orphanet. J. Rare Dis. 2016;11:159. doi: 10.1186/s13023-016-0543-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 155.Zhang J., Tripathi D.N., Jing J., Alexander A., Kim J., Powell R.T., Dere R., Tait-Mulder J., Lee J.-H., Paull T.T., et al. ATM Functions at the Peroxisome to Induce Pexophagy in Response to ROS. Nat. Cell Biol. 2015;17:1259–1269. doi: 10.1038/ncb3230. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 156.Alexander A., Cai S.L., Kim J., Nanez A., Sahin M., MacLean K.H., Inoki K., Guan K.L., Shen J., Person M.D., et al. ATM Signals to TSC2 in the Cytoplasm to Regulate mTORC1 in Response to ROS. Proc. Natl. Acad. Sci. USA. 2010;107:4153–4158. doi: 10.1073/pnas.0913860107. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 157.Marzetti E., Calvani R., Coelho-Júnior H.J., Landi F., Picca A. Mitochondrial Quantity and Quality in Age-Related Sarcopenia. Int. J. Mol. Sci. 2024;25:2052. doi: 10.3390/ijms25042052. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 158.Edwards M.H., Dennison E.M., Aihie Sayer A., Fielding R., Cooper C. Osteoporosis and Sarcopenia in Older Age. Bone. 2015;80:126–130. doi: 10.1016/j.bone.2015.04.016. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 159.Tenchov R., Sasso J.M., Wang X., Zhou Q.A. Aging Hallmarks and Progression and Age-Related Diseases: A Landscape View of Research Advancement. ACS Chem. Neurosci. 2024;15:1–30. doi: 10.1021/acschemneuro.3c00531. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 160.Peeters A., Shinde A.B., Dirkx R., Smet J., De Bock K., Espeel M., Vanhorebeek I., Vanlander A., Van Coster R., Carmeliet P., et al. Mitochondria in Peroxisome-Deficient Hepatocytes Exhibit Impaired Respiration, Depleted DNA, and PGC-1α Independent Proliferation. Biochim. Biophys. Acta. 2015;1853:285–298. doi: 10.1016/j.bbamcr.2014.11.017. [DOI] [PubMed] [Google Scholar]
- 161.Nuebel E., Morgan J.T., Fogarty S., Winter J.M., Lettlova S., Berg J.A., Chen Y.C., Kidwell C.U., Maschek J.A., Clowers K.J., et al. The Biochemical Basis of Mitochondrial Dysfunction in Zellweger Spectrum Disorder. EMBO Rep. 2021;22:e51991. doi: 10.15252/embr.202051991. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 162.Xie Z., Zhang X., Li Y., Zhu R. Mitochondrial Dysfunction Drives Cellular Senescence: Molecular Mechanisms of Inter-Organelle Communication. Exp. Gerontol. 2025;211:112913. doi: 10.1016/j.exger.2025.112913. [DOI] [PubMed] [Google Scholar]
- 163.Weir H.J., Yao P., Huynh F.K., Escoubas C.C., Goncalves R.L., Burkewitz K., Laboy R., Hirschey M.D., Mair W.B. Dietary Restriction and AMPK Increase Lifespan via Mitochondrial Network and Peroxisome Remodeling. Cell Metab. 2017;26:884–896.e5. doi: 10.1016/j.cmet.2017.09.024. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 164.Papsdorf K., Miklas J.W., Hosseini A., Cabruja M., Morrow C.S., Savini M., Yu Y., Silva-García C.G., Haseley N.R., Murphy L.M., et al. Lipid Droplets and Peroxisomes Are Co-Regulated to Drive Lifespan Extension in Response to Mono-Unsaturated Fatty Acids. Nat. Cell Biol. 2023;25:672–684. doi: 10.1038/s41556-023-01136-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 165.Wu N., Ma Y.C., Gong X.Q., Zhao P.J., Jia Y.J., Zhao Q., Duan J.H., Zou C.G. The Metabolite Alpha-Ketobutyrate Extends Lifespan by Promoting Peroxisomal Function in C. elegans. Nat. Commun. 2023;14:240. doi: 10.1038/s41467-023-35899-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 166.Cedillo L., Ahsan F.M., Li S., Stuhr N.L., Zhou Y., Zhang Y., Adedoja A., Murphy L.M., Yerevanian A., Emans S., et al. Ether Lipid Biosynthesis Promotes Lifespan Extension and Enables Diverse Pro-Longevity Paradigms in Caenorhabditis elegans. elife. 2023;12:e82210. doi: 10.7554/eLife.82210. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 167.Lismont C., Nordgren M., Brees C., Knoops B., Van Veldhoven P.P., Fransen M. Peroxisomes as Modulators of Cellular Protein Thiol Oxidation: A New Model System. Antioxid. Redox Signal. 2019;30:22–39. doi: 10.1089/ars.2017.6997. [DOI] [PubMed] [Google Scholar]
- 168.Kim E.H., Ridlo M.R., Lee B.C., Kim G.A. Crosstalk between Peroxisomal Activities and Nrf2 Signaling in Porcine Embryos. Antioxidants. 2021;10:771. doi: 10.3390/antiox10050771. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 169.Zhu X., Chen Z., Shen W., Huang G., Sedivy J.M., Wang H., Ju Z. Inflammation, Epigenetics, and Metabolism Converge to Cell Senescence and Ageing: The Regulation and Intervention. Signal Transduct. Target. Ther. 2021;6:245. doi: 10.1038/s41392-021-00646-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 170.Chen J., Liu B., Yao X., Yang X., Sun J., Yi J., Xue F., Zhang J., Shen Y., Chen B., et al. AMPK/SIRT1/PGC-1α Signaling Pathway: Molecular Mechanisms and Targeted Strategies from Energy Homeostasis Regulation to Disease Therapy. CNS Neurosci. Ther. 2025;31:e70657. doi: 10.1111/cns.70657. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 171.Hua C., Zhang G., Yu W., Zhou J., Ru L., Xue G., Zheng L., Wang M., Wang Y., Yu D., et al. CROT Overactivation within Peroxisomes Confers Chemoresistance to Non-Small Cell Lung Cancer by Targeting Fatty Acid Oxidation-Nrf2-Ferroptosis Resistance Axis. Pharmacol. Res. 2025;220:107911. doi: 10.1016/j.phrs.2025.107911. [DOI] [PubMed] [Google Scholar]
- 172.Vaziri N.D. Protective Effect of Nrf2 and Catalase in Maternal Diabetes-Induced Perinatal Hypertension and Kidney Disease. Diabetes. 2012;61:2400–2402. doi: 10.2337/db12-0764. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 173.Sharma A., Smith H.J., Yao P., Mair W.B. Causal Roles of Mitochondrial Dynamics in Longevity and Healthy Aging. EMBO Rep. 2019;20:e48395. doi: 10.15252/embr.201948395. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 174.Li H., Lismont C., Revenco I., Hussein M.A.F., Costa C.F., Fransen M. The Peroxisome-Autophagy Redox Connection: A Double-Edged Sword? Front. Cell Dev. Biol. 2021;9:814047. doi: 10.3389/fcell.2021.814047. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 175.Germain K., So R.W.L., DiGiovanni L.F., Watts J.C., Bandsma R.H.J., Kim P.K. Upregulated Pexophagy Limits the Capacity of Selective Autophagy. Nat. Commun. 2024;15:375. doi: 10.1038/s41467-023-44005-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 176.Van Veldhoven P.P., Baes M. Peroxisome Deficient Invertebrate and Vertebrate Animal Models. Front. Physiol. 2013;4:335. doi: 10.3389/fphys.2013.00335. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 177.Kim H., Haluzik M., Asghar Z., Yau D., Joseph J.W., Fernandez A.M., Reitman M.L., Yakar S., Stannard B., Heron-Milhavet L., et al. Peroxisome Proliferator-Activated Receptor-Alpha Agonist Treatment in a Transgenic Model of Type 2 Diabetes Reverses the Lipotoxic State and Improves Glucose Homeostasis. Diabetes. 2003;52:1770–1778. doi: 10.2337/diabetes.52.7.1770. [DOI] [PubMed] [Google Scholar]
- 178.Sheikh K., Camejo G., Lanne B., Halvarsson T., Landergren M.R., Oakes N.D. Beyond Lipids, Pharmacological PPARalpha Activation Has Important Effects on Amino Acid Metabolism as Studied in the Rat. Am. J. Physiol. Endocrinol. Metab. 2007;292:E1157–E1165. doi: 10.1152/ajpendo.00254.2006. [DOI] [PubMed] [Google Scholar]
- 179.Kersten S. Peroxisome Proliferator Activated Receptors and Lipoprotein Metabolism. PPAR Res. 2008;2008:132960. doi: 10.1155/2008/132960. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 180.Bougarne N., Weyers B., Desmet S.J., Deckers J., Ray D.W., Staels B., De Bosscher K. Molecular Actions of PPARα in Lipid Metabolism and Inflammation. Endocr. Rev. 2018;39:760–802. doi: 10.1210/er.2018-00064. [DOI] [PubMed] [Google Scholar]
- 181.Botta M., Audano M., Sahebkar A., Sirtori C.R., Mitro N., Ruscica M. PPAR Agonists and Metabolic Syndrome: An Established Role? Int. J. Mol. Sci. 2018;19:1197. doi: 10.3390/ijms19041197. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 182.AlNafea H.M., Korish A.A. Activation of the Peroxisome Proliferator-Activated Receptors (PPAR-α/γ) and the Fatty Acid Metabolizing Enzyme Protein CPT1A by Camel Milk Treatment Counteracts the High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease. PPAR Res. 2021;2021:5558731. doi: 10.1155/2021/5558731. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 183.Lin Y., Wang Y., Li P.F. PPARα: An Emerging Target of Metabolic Syndrome, Neurodegenerative and Cardiovascular Diseases. Front. Endocrinol. 2022;13:1074911. doi: 10.3389/fendo.2022.1074911. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 184.Itoyama A., Honsho M., Abe Y., Moser A., Yoshida Y., Fujiki Y. Docosahexaenoic Acid Mediates Peroxisomal Elongation, a Prerequisite for Peroxisome Division. J. Cell Sci. 2012;125:589–602. doi: 10.1242/jcs.087452. [DOI] [PubMed] [Google Scholar]
- 185.Zhang R., Chen L., Jiralerspong S., Snowden A., Steinberg S., Braverman N. Recovery of PEX1-Gly843Asp Peroxisome DysFunction by Small-Molecule Compounds. Proc. Natl. Acad. Sci. USA. 2010;107:5569–5574. doi: 10.1073/pnas.0914960107. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 186.Wood P.L., Khan M.A., Smith T., Ehrmantraut G., Jin W., Cui W., Braverman N.E., Goodenowe D.B. In vitro and In Vivo Plasmalogen Replacement evaluations in Rhizomelic Chrondrodysplasia Punctata and Pelizaeus-Merzbacher Disease Using PPI-1011, an Ether Lipid Plasmalogen Precursor. Lipids Health Dis. 2011;10:182. doi: 10.1186/1476-511X-10-182. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 187.Berendse K., Ebberink M.S., Ijlst L., Poll-The B.T., Wanders R.J., Waterham H.R. Arginine Improves Peroxisome Functioning in Cells from Patients with a Mild Peroxisome Biogenesis Disorder. Orphanet. J. Rare Dis. 2013;8:138. doi: 10.1186/1750-1172-8-138. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 188.MacLean G.E., Argyriou C., Di Pietro E., Sun X., Birjandian S., Saberian P., Hacia J.G., Braverman N.E. Zellweger Spectrum Disorder Patient-Derived Fibroblasts with the PEX1-Gly843Asp Allele Recover Peroxisome Functions in Response to Flavonoids. J. Cell Biochem. 2019;120:3243–3258. doi: 10.1002/jcb.27591. [DOI] [PubMed] [Google Scholar]
- 189.Huang T.Y., Zheng D., Houmard J.A., Brault J.J., Hickner R.C., Cortright R.N. Overexpression of PGC-1α Increases Peroxisomal Activity and Mitochondrial Fatty Acid Oxidation in Human Primary Myotubes. Am. J. Physiol. Endocrinol. Metab. 2017;312:E253–E263. doi: 10.1152/ajpendo.00331.2016. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 190.Eun S.Y., Lee J.N., Nam I.K., Liu Z.Q., So H.S., Choe S.K., Park R. PEX5 Regulates Autophagy via the mTORC1-TFEB Axis During Starvation. Exp. Mol. Med. 2018;50:1–12. doi: 10.1038/s12276-017-0007-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 191.Duszka K., Gregor A., Guillou H., König J., Wahli W. Peroxisome Proliferator-Activated Receptors and Caloric Restriction-Common Pathways Affecting Metabolism, Health, and Longevity. Cells. 2020;9:1708. doi: 10.3390/cells9071708. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 192.Popov D.V., Bachinin A.V., Lysenko E.A., Miller T.F., Vinogradova O.L. Exercise-Induced Expression of Peroxisome Proliferator-Activated Receptor γ Coactivator-1α Isoforms in Skeletal Muscle of Endurance-Trained Males. J. Physiol. Sci. 2014;64:317–323. doi: 10.1007/s12576-014-0321-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 193.Huang T.Y., Linden M.A., Fuller S.E., Goldsmith F.R., Simon J., Batdorf H.M., Scott M.C., Essajee N.M., Brown J.M., Noland R.C. Combined Effects of a Ketogenic Diet and Exercise Training Alter Mitochondrial and Peroxisomal Substrate Oxidative Capacity in Skeletal Muscle. Am. J. Physiol. Endocrinol. Metab. 2021;320:E1053–E1067. doi: 10.1152/ajpendo.00410.2020. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 194.Nakajima T., Tanaka N., Li G., Hu R., Kamijo Y., Hara A., Aoyama T. Effect of Bezafibrate on Hepatic Oxidative Stress: Comparison between Conventional Experimental Doses and Clinically-Relevant Doses in Mice. Redox Rep. 2010;15:123–130. doi: 10.1179/174329210X12650506623807. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 195.Hakimizadeh E., Tadayon S., Zamanian M.Y., Soltani A., Giménez-Llort L., Hassanipour M., Fatemi I. Gemfibrozil, a Lipid-Lowering Drug, Improves Hepatorenal Damages in a Mouse Model of Aging. Fundam. Clin. Pharmacol. 2023;37:599–605. doi: 10.1111/fcp.12865. [DOI] [PubMed] [Google Scholar]
- 196.Kim J.Y., Zhou D., Cui X.S. Bezafibrate Prevents Aging in In Vitro-Matured Porcine Oocytes. J. Anim. Sci. Technol. 2021;63:766–777. doi: 10.5187/jast.2021.e64. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 197.Yammine A., Zarrouk A., Nury T., Vejux A., Latruffe N., Vervandier-Fasseur D., Samadi M., Mackrill J.J., Greige-Gerges H., Auezova L., et al. Prevention by Dietary Polyphenols (Resveratrol, Quercetin, Apigenin) Against 7-Ketocholesterol-Induced Oxiapoptophagy in Neuronal N2a Cells: Potential Interest for the Treatment of Neurodegenerative and Age-Related Diseases. Cells. 2020;9:2346. doi: 10.3390/cells9112346. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 198.Shukla N., Neal M.L., Farré J.C., Mast F.D., Sarkar R., Truong L., Simon T., Miller L.R., Aitchison J.D., Subramani S. TOR and Heat Shock Response Pathways Regulate Peroxisome Biogenesis During Proteotoxic Stress. Nat. Commun. 2025;16:10743. doi: 10.1038/s41467-025-65776-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
All information in this review is derived from published literature cited in the manuscript; no new data were generated or analyzed, and data sharing is therefore not applicable.



